Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

ACIP logo The Advisory Committee on Immunization Practices (ACIP) is a group of medical and public health experts that develop recommendations on use of vaccines in the civilian population of the United States…

More


Register for upcoming October ACIP meeting

October 24-25, 2018

laptop

Deadline for registration:
Non-US Citizens: September 26, 2018
US Citizens: October 10, 2018

Registration is NOT required to watch the live meeting webcast or to listen via telephone.

Live Webcast Instructions

Public Comment Instructions [1 page]


ACIP Recommendations


General Committee-related Information

  • Charter
    Defines ACIP's purpose, authority, and function; its structure, meetings, and compensation; plus costs, reports, and termination.
  • Members
    Membership roster, including chair, executive secretary, voting members, ex officio members, and liaison representatives.
  • Articles
    Journal articles about the ACIP.

Guidance


ACIP Flyer

ACIP brochure This ACIP flyer [2 pages] answers questions such as what does the ACIP consider in the vaccine recommendation process, including recommended ages for administration of various vaccines to children?

On November 9, 2017, FDA approved a new hepatitis B vaccine, HEPLISAV-B®, for use in adults 18 years of age and older.  HEPLISAV-B® is the first licensed vaccine using a CpG adjuvant* and is administered as two doses given one month apart.  Further details on this vaccine’s approval can be found at Vaccines Licensed for Use in the United States.

*Cytosine phosphoguanine (CpG) 1018 adjuvant

June 2018 Meeting Recommendations

ACIP approved the following recommendations by majority vote at its June 2018 meeting:

  • Reaffirmed the seasonal influenza recommendations for the 2018-2019 influenza season
  • Anthrax vaccine use for post-exposure prophylaxis in a mass vaccination campaign, including:
    • The intramuscular route of administration may be used if the subcutaneous route of administration presents clinical, operational, or logistical challenges that may delay or prevent effective vaccination
    • Should there be an inadequate supply of anthrax vaccine available for post-exposure prophylaxis, either 2 full doses or 3 half doses of anthrax vaccine absorbed (AVA) may be used to expand vaccine coverage
    • In immunocompetent adults aged 18 through 65 years, antimicrobials given in conjunction with vaccine may be discontinued at 42 days after the first vaccine dose or 2 weeks after the last vaccine dose, whichever comes later

These recommendations have been adopted by the CDC Director and will become official once published in MMWR.


ACIP Meetings


TOP